Clinical and Laboratory Characteristics of Pediatric Patients With ACKR1/DARC-Associated Neutropenia

IF 2.4 3区 医学 Q2 HEMATOLOGY
Lital Oz-Alcalay, Orna Steinberg-Shemer, Eyal Elron, Michal Dvori, Sarah Elitzur, Orly Dgany, Sharon Noy-Lotan, Tanya Krasnov, Hannah Tamary, Dafna Brik-Simon, Joanne Yacobovich, Oded Gilad
{"title":"Clinical and Laboratory Characteristics of Pediatric Patients With ACKR1/DARC-Associated Neutropenia","authors":"Lital Oz-Alcalay,&nbsp;Orna Steinberg-Shemer,&nbsp;Eyal Elron,&nbsp;Michal Dvori,&nbsp;Sarah Elitzur,&nbsp;Orly Dgany,&nbsp;Sharon Noy-Lotan,&nbsp;Tanya Krasnov,&nbsp;Hannah Tamary,&nbsp;Dafna Brik-Simon,&nbsp;Joanne Yacobovich,&nbsp;Oded Gilad","doi":"10.1002/pbc.31430","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>ACKR1/DARC-associated neutropenia (ADAN), resulting from homozygosity for a single nucleotide polymorphism (SNP) in the <i>ACKR1/DARC</i> gene (rs2814778), is a common cause of benign neutropenia that primarily affects individuals of African and Jewish Yemenite descent. We aimed to characterize ADAN in pediatric patients in Israel, given its ethnically diverse population.</p>\n </section>\n \n <section>\n \n <h3> Procedure</h3>\n \n <p>We assessed children with isolated neutropenia treated during 2018–2023 at one pediatric center, for the <i>ACKR1/DARC</i> polymorphism, using Sanger sequencing or targeted next-generation sequencing.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of 115 patients evaluated, 49 (42.6%) were diagnosed with ADAN; of these, 29 (59%) had absolute neutrophil counts in the severe range (0–0.5 × 10<sup>9</sup>/L) at diagnosis. The allele distribution revealed 37% of Muslim Arab and 61% of Jewish origin. Yemenite, Ethiopian, Mediterranean, Asian, and European ancestry were included; 59% had a family history of neutropenia. The median age at the first neutropenia detection was 1.2 years; 91.8% were identified during routine blood counts. The median absolute neutrophil count at diagnosis was 0.5 × 10<sup>9</sup>/L (interquartile range: 0.3). An increased susceptibility to infections was not found either before or during the median follow-up period of 2.5 years (interquartile range: 1.54) after the diagnosis of ADAN. In 34 patients (72.3%), neutrophil counts were in the normal range during febrile illnesses.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>We identified ADAN in individuals of variable ethnicities, almost half with severe neutropenia. We recommend testing for ADAN in all children with isolated neutropenia without severe infections. Homozygosity for the <i>ACKR1/DARC</i> rs2814778 SNP may obviate the need for further investigation, follow-up, or treatment in specific clinical scenarios.</p>\n </section>\n </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 1","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31430","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pbc.31430","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

ACKR1/DARC-associated neutropenia (ADAN), resulting from homozygosity for a single nucleotide polymorphism (SNP) in the ACKR1/DARC gene (rs2814778), is a common cause of benign neutropenia that primarily affects individuals of African and Jewish Yemenite descent. We aimed to characterize ADAN in pediatric patients in Israel, given its ethnically diverse population.

Procedure

We assessed children with isolated neutropenia treated during 2018–2023 at one pediatric center, for the ACKR1/DARC polymorphism, using Sanger sequencing or targeted next-generation sequencing.

Results

Of 115 patients evaluated, 49 (42.6%) were diagnosed with ADAN; of these, 29 (59%) had absolute neutrophil counts in the severe range (0–0.5 × 109/L) at diagnosis. The allele distribution revealed 37% of Muslim Arab and 61% of Jewish origin. Yemenite, Ethiopian, Mediterranean, Asian, and European ancestry were included; 59% had a family history of neutropenia. The median age at the first neutropenia detection was 1.2 years; 91.8% were identified during routine blood counts. The median absolute neutrophil count at diagnosis was 0.5 × 109/L (interquartile range: 0.3). An increased susceptibility to infections was not found either before or during the median follow-up period of 2.5 years (interquartile range: 1.54) after the diagnosis of ADAN. In 34 patients (72.3%), neutrophil counts were in the normal range during febrile illnesses.

Conclusions

We identified ADAN in individuals of variable ethnicities, almost half with severe neutropenia. We recommend testing for ADAN in all children with isolated neutropenia without severe infections. Homozygosity for the ACKR1/DARC rs2814778 SNP may obviate the need for further investigation, follow-up, or treatment in specific clinical scenarios.

Abstract Image

ACKR1/DARC 相关性中性粒细胞减少症儿科患者的临床和实验室特征
背景:ACKR1/DARC 相关性中性粒细胞减少症(ADAN)是由 ACKR1/DARC 基因(rs2814778)中的单核苷酸多态性(SNP)同源性引起的,是良性中性粒细胞减少症的常见病因,主要影响非洲裔和也门裔犹太人。鉴于以色列人口的种族多样性,我们旨在了解以色列儿科患者 ADAN 的特征:我们使用桑格测序法或定向下一代测序法对 2018-2023 年期间在一家儿科中心接受治疗的孤立性中性粒细胞减少症患儿进行了 ACKR1/DARC 多态性评估:在接受评估的115名患者中,49人(42.6%)被诊断为ADAN;其中29人(59%)在诊断时绝对中性粒细胞计数处于严重范围(0-0.5 × 109/L)。等位基因分布显示,37% 的人来自阿拉伯穆斯林,61% 的人来自犹太血统。其中包括也门、埃塞俄比亚、地中海、亚洲和欧洲血统;59%的患者有中性粒细胞减少症家族史。首次发现中性粒细胞减少症的中位年龄为 1.2 岁;91.8% 是在常规血细胞计数中发现的。确诊时中性粒细胞绝对计数的中位数为 0.5 × 109/L(四分位数间距:0.3)。在确诊 ADAN 前或确诊后 2.5 年(四分位数间距:1.54)的中位随访期间,均未发现感染易感性增加的情况。34名患者(72.3%)在发热期间中性粒细胞计数处于正常范围:我们在不同种族的患者中发现了 ADAN,其中近一半患者患有严重的中性粒细胞减少症。我们建议对所有无严重感染的孤立性中性粒细胞减少症患儿进行 ADAN 检测。ACKR1/DARC rs2814778 SNP 的同源性可能会在特定的临床情况下避免进一步的调查、随访或治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pediatric Blood & Cancer
Pediatric Blood & Cancer 医学-小儿科
CiteScore
4.90
自引率
9.40%
发文量
546
审稿时长
1.5 months
期刊介绍: Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信